AbbVie's elagolix has shown promise in a phase 2 trial in women with uterine fibroids, a second indication for the pipeline drug, which could become a major earner for the company.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
